ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01320085
Recruitment Status : Active, not recruiting
First Posted : March 22, 2011
Last Update Posted : May 30, 2018
Sponsor:
Information provided by (Responsible Party):
Array BioPharma

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Active, not recruiting
  Actual Primary Completion Date : January 7, 2014
  Estimated Study Completion Date : June 30, 2019
  Certification/Extension First Submitted : January 30, 2017